✦ LIBER ✦

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis

✍ Scribed by Franz Fazekas; Florian Deisenhammer; Siegrid Strasser-Fuchs; Gerhard Nahler; Bruno Mamoli

Book ID: 118560376
Publisher: The Lancet
Year: 1997
Tongue: English
Weight: 46 KB
Volume: 349
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(96)09377-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Indications des immunoglobulines intrave

Indications des immunoglobulines intraveineuses: F Fazekas, F Diesenhammer, S Strasser-Fuchs et al Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis Lancet 1997;349:589–93

✍ Julie Cosserat 📂 Article 📅 1997 🏛 Elsevier Science 🌐 French ⚖ 114 KB

Intravenous immunoglobulin treatment in

Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A randomized, double-blind multicenter, placebo-controlled trial

✍ A. Achiron; R. Gilad; S. Hassin; Y. Barak; U. Gabbay; I. Ziv; Y. Goldhamer; E. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Intravenous immunoglobulin in secondary

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial

✍ Otto R Hommes; Per S Sørensen; Franz Fazekas; Monika Maas Enriquez; Hans W Koelm 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 175 KB

Open controlled therapeutic trial of int

Open controlled therapeutic trial of intravenous immunoglobulins in relapsing-remitting multiple sclerosis

✍ A. Achiron; E. Pras; R. Gilad; C.R. Gordon; I. Ziv; I. Sarova-Pinhas; E. Melamed 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

Ocrelizumab in relapsing-remitting multi

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB

## Background: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. we aimed to assess efficacy and safety of two dose regimens of the humanised anti-cd20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ## Methods: We did a multicentre,